- Home
- Publications
- Publication Search
- Publication Details
Title
Selective JAK inhibitors in development for rheumatoid arthritis
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 23, Issue 8, Pages 1067-1077
Publisher
Informa Healthcare
Online
2014-05-12
DOI
10.1517/13543784.2014.918604
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- THU0252 Relationship between Lymphocyte Count and Risk of Infection in Rheumatoid Arthritis Patients Treated with Tofacitinib
- (2014) R. van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis
- (2014) E. Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- A1.72 Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study1
- (2014) Peter Taylor et al. ANNALS OF THE RHEUMATIC DISEASES
- Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1
- (2013) Christopher A. Hurley et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Tofacitinib: A Review of its Use in Adult Patients with Rheumatoid Arthritis
- (2013) Lesley J. Scott DRUGS
- Lead identification of novel and selective TYK2 inhibitors
- (2013) Jun Liang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Tyk2 is a therapeutic target for psoriasis-like skin inflammation
- (2013) M. Ishizaki et al. INTERNATIONAL IMMUNOLOGY
- Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration
- (2013) Hal E. Broxmeyer JOURNAL OF EXPERIMENTAL MEDICINE
- A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors
- (2013) S. J. Sohn et al. JOURNAL OF IMMUNOLOGY
- Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
- (2013) L. Van Rompaey et al. JOURNAL OF IMMUNOLOGY
- Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2
- (2013) Mark Zak et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis
- (2013) J. S. Nijjar et al. RHEUMATOLOGY
- Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study
- (2012) C Balagué et al. BRITISH JOURNAL OF PHARMACOLOGY
- Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
- (2012) Kris Vaddi et al. EXPERT OPINION ON PHARMACOTHERAPY
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)
- (2012) Anders Poulsen et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis
- (2012) B. Madan et al. JOURNAL OF IMMUNOLOGY
- Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis
- (2012) Anthony D. William et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors
- (2012) Janusz J. Kulagowski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Kinase inhibitors: a new class of antirheumatic drugs
- (2012) Vasileios Kyttaris Drug Design Development and Therapy
- Specific Jak3 Downregulation in Lymphocytes Impairs γc Cytokine Signal Transduction and Alleviates Antigen-driven Inflammation In Vivo
- (2012) Alicia G Gómez-Valadés et al. Molecular Therapy-Nucleic Acids
- Role of Spleen Tyrosine Kinase Inhibitors in the Management of Rheumatoid Arthritis
- (2011) David L. Scott DRUGS
- New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors
- (2011) M. G. Bonilla-Hernan et al. RHEUMATOLOGY
- Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
- (2011) S Hart et al. Blood Cancer Journal
- Kinase inhibitors: a new approach to rheumatoid arthritis treatment
- (2010) Stanley Cohen et al. CURRENT OPINION IN RHEUMATOLOGY
- Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
- (2010) J. S. Fridman et al. JOURNAL OF IMMUNOLOGY
- Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis
- (2009) Stanley B. Cohen et al. ARTHRITIS AND RHEUMATISM
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory Disorders
- (2009) David M. Goldstein et al. JOURNAL OF MEDICINAL CHEMISTRY
- p38MAPK: stress responses from molecular mechanisms to therapeutics
- (2009) Lydia R. Coulthard et al. TRENDS IN MOLECULAR MEDICINE
- Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)
- (2008) Jian-kang Jiang et al. JOURNAL OF MEDICINAL CHEMISTRY
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started